Neurotoxicity Research

, Volume 5, Issue 8, pp 579–598 | Cite as

Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists

  • Steven P. Presgraves
  • Tariq Ahmed
  • Sabine Borwege
  • Jeffrey N. Joyce


We characterized undifferentiated (UN) and three differentiation conditions of the SH-SY5Y neuroblastoma cell line for phenotypic markers of dopaminergic cells, sensitivity to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridinium ion (MPP), the requirement to utilize the dopamine (DA) transporter (DAT) for MPP toxicity, and the neuroprotective effects of pramipexole. Cells were differentiated with retinoic acid (RA), 12-O-tetradecanoly-phorbol-13-acetate (TPA), and RA followed by TPA (RA/TPA). RA/TPA treated cells exhibited the highest levels of tyrosine hydroxylase and DAT but lower levels of vesicular monoamine transporter. The kinetics of [3H]DA uptake and [3H]MPP uptake to DAT in RA/TPA differentiated cells were similar to that of rat and mouse caudate-putamen synaptosomes. RA/TPA differentiated cells evidenced high sensitivity to the neurotoxic effects of MPP (0.03 to 3.0 mM), and the neurotoxic effects of MPP were blocked with the DAT inhibitor 1-(2-[bis(4-fluorophenyl)methoxy]ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909). DA-induced cell death was not more sensitive in RA vs RA/TPA differentiated cells and was not inhibited by transporter inhibitors. RA/TPA differentiated cells exhibited 3- fold and 6-fold higher levels, respectively, of DA D2 and D3 receptors than UN or RA differentiated cells. Pretreatment with pramipexole was protective against MPP in the RA/TPA differentiated cells but not in undifferentiated or RA differentiated cells. The neuroprotective effect of pramipexole was concentration-dependent and dopamine D2/D3 receptor dependent. In contrast, protection by pramipexole against DA was not DA receptor dependent. Further characterization of the neuroprotective effects of DA agonists in this model system can provide unique information about DA receptor dependent and independent mechanisms of neuroprotection.


Parkinson's disease D2 Receptor D3 Receptor MPP Dopamine transporter Pramipexole 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ammer H and R Schulz (1994) Retinoic acid-induced differentiation of human neuroblastoma SH-SY5Y cells is associated with changes in the abundance of G proteins.J. Neurochem. 62, 1310–1318.PubMedGoogle Scholar
  2. Anderson, DW, T Neavin, JA Smith and JS Schneider (2001) Neuroprotective effects of pramipexole in young and aged MPTP-treated mice.Brain Res. 905, 44–53.PubMedCrossRefGoogle Scholar
  3. Biedler JL, S Roffler-Tarlov., M Schachner and LS Freedman (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones.Cancer Res. 38, 3751–3757.PubMedGoogle Scholar
  4. Bilsland J, S Roy, S Xanthoudakis, DW Nicholson, Y Han, E Grimm, F Hefti and SJ Harper (2002) Caspase inhibitors attenuate 1-methyl-4-phenylpyridinium toxicity in primary cultures of mesencephalic dopaminergic neurons.J. Neurosci. 22, 2637–2649.PubMedGoogle Scholar
  5. Blum D, S Torch, N Lambeng, M Nissou, AL Benabid, R Sadoul and JM Verna (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.Prog. Neurobiol. 65, 135–172.PubMedCrossRefGoogle Scholar
  6. Burns RS, CC Chiueh, SP Markey, MH Ebert, DM Jacobowitz and IJ Kopin (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra byN-methyl-4- phenyl-1,2,3,6-tetrahydropyridine.Proc. Natl. Acad. Sci. USA 80, 4546–4550.PubMedCrossRefGoogle Scholar
  7. Carvey PM and ZD Ling (1997) The case for neuroprotection with dopamine agonistsClin. Neuropharmacol. 20 [Suppl.], S8-S21.Google Scholar
  8. Carvey PM, S Pieri and ZD Ling (1997) Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.J. Neuroal Transm. 104, 209–228.CrossRefGoogle Scholar
  9. Carvey PM, SO McGuire and ZD Ling (2001) Neuroprotective effects of D3 dopamine receptor agonists.Parkinsonism Relat. Disord. 7, 213–223.PubMedCrossRefGoogle Scholar
  10. Cassarino DS and JP Bennett Jr (1999) An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration.Brain Res. Brain Res. Rev. 29, 1–25.PubMedCrossRefGoogle Scholar
  11. Cassarino DS, CP Fall, TS Smith and JP Bennett Jr (1998) Pramipexole reduces reactive oxygen species productionin vivo andin vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.J. Neurochem. 71, 295–301.PubMedGoogle Scholar
  12. Choi WS, Y Yoon, TH Oh, EJ Choi, KL O'Malley and YJ Oh (1999) Two distinct mechanisms are involved in 6-hydroxydopamine-and MPP-induced dopaminergic neuronal cell death: role of caspases, ROS and JNK.J. Neurosci. Res. 57, 86–94.PubMedCrossRefGoogle Scholar
  13. Chun HS, GE Gibson, LA DeGiorgio, H Zhang, VJ Kidd and JH Son (2001) Dopaminergic cell death induced by MPP, oxidant and specific neurotoxicants, shares the common molecular mechanism.J. Neurochem. 76, 1010–1021.PubMedCrossRefGoogle Scholar
  14. Cohen G and P, Werner (1994) Free radicals, oxidative stress and neurodegeneration, inNeurodegenerative Disorders (Calne DB, Ed.) (WB Saunders, Philadelphia, PA), pp. 139–162.Google Scholar
  15. Diaz J, C Pilon, B Le Foll, C, Gros, A Triller, JC Schwartz and P Sokoloff (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci.20, 8677–8684.PubMedGoogle Scholar
  16. Dickinson SD, J Sabeti, GA Larson, K Giardina, M Rubinstein, MA Kelly, DK Grandy, MJ Low, GA Gerhardt and NR Zahniser (1999) Dopamine D2 receptor-deficient mice exhibit decreased dopamine transporter function but no changes in dopamine release in dorsal striatum.J. Neurochem. 72, 148–156.PubMedCrossRefGoogle Scholar
  17. Eshleman AJ, E Stewart, AK Evenson, JN Mason, RD Blakely, A Janowsky and KA Neve (1997) Metabolism of catecholamines by catechol-O-methyltransferase in cells expressing recombinant catecholamine transportersJ. Neurochem. 69, 1459–1466.PubMedGoogle Scholar
  18. Eshleman AJ, K Wolfrum, DC Mash, K Christensen and A Janowsky (2001) Drug interactions with the dopamine transporter in cryopreserved human caudate.J. Pharm. Exp. Ther. 296, 442–449.Google Scholar
  19. Fall CP and JP Bennett Jr (1999) Characterization and time course of MPP-induced apoptosis in human SH-SY5Y neuroblastoma cells.J. Neurosci. Res. 55, 620–628.PubMedCrossRefGoogle Scholar
  20. Fang J, D Zuo and PH Yu (1995) Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxinN-methyl-4-phenylpyridinium (MPP) towards cultured dopaminergic neuroblastoma cells.Psychopharmacology (Berl.) 121, 373–378.CrossRefGoogle Scholar
  21. Farooqui SM (1994) Induction of adenylate cyclase sensitive dopamine D2-receptors in retinoic acid induced differentiated human neuroblastoma SHSY-5Y cells.Life Sci. 55, 1887–1893.PubMedCrossRefGoogle Scholar
  22. Gainetdinov RR, F Fumagalli, SR Jones and MG Caron (1997) Dopamine transporter is required forin vivo MPTP neurotoxicity: evidence from mice lacking the transporter.J. Neurochem. 69, 1322–1325.PubMedCrossRefGoogle Scholar
  23. Gobert A, JM Rivet, V Audinot, L Cistarelli, M Spedding, J Vian, JL Peglion and MJ Millan (1995) Functional correlates of dopamine D3 receptor activation in the ratin vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and “silent” D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways.J. Phar. Exp. Ther. 275, 899–913.Google Scholar
  24. Gómez C, J Reiriz, M Pique, J Gil, I Ferrer and S Ambrosio (2001) Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells.J. Neurosci. Rev. 63, 421–428.CrossRefGoogle Scholar
  25. Gómez-Santos C, I Ferrer, AF Santidrian, M Barrachina, J Gil and S Ambrosio (2003) Dopamine induces autophagic cell death and alpha-synuclein increase, in human neuroblastoma SH-SY5Y cells.J. Neurosci. Res. 73, 341–350.PubMedCrossRefGoogle Scholar
  26. Grünblatt E, S Mandel, T Berkuzki and MB Youdim (1999) Apomorphine protects against MPTP-induced neurotoxicity in mice.Mov. Disord. 14, 612–618.PubMedCrossRefGoogle Scholar
  27. Hirsch EC, S Hunot and A Hartmann (2000) Mechanism of cell death in experimental models of Parkinson's disease.Funct. Neurol. 15, 229–237.PubMedGoogle Scholar
  28. Hornykiewicz O (1998) Biochemical aspects of Parkinson's disease.Neurology 51, S2-S9.PubMedGoogle Scholar
  29. Iida M, I Miyazaki, K Tanaka, H Kabuto, E Iwata-Ichikawa and N Ogawa (1999) Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.Brain Res. 838, 51–59.PubMedCrossRefGoogle Scholar
  30. Itano Y and Y Nomura (1995) 1-methyl-4-phenyl-pyridinium ion (MPP) causes DNA fragmentation and increases the Bcl-2 expression in human neuroblastoma, SH-SY5Y cells, through different mechanisms.Brain Res. 704, 240–245.PubMedCrossRefGoogle Scholar
  31. Jones DC, PG Gunasekar, JL Borowitz and GE Isom (2000) Dopamine-induced apoptosis is mediated by oxidative stress and is enhanced by cyanide in differentiated PC12 cells.J. Neurochem. 74, 2296–2304.PubMedCrossRefGoogle Scholar
  32. Jung, M-Y, BV Skryabin, M Arai, S Abbondanzo, D Fu, J Brosius, NK Robakis, HG Polites, JE Pintar and C Schmauss (1999) Potentiation of the D2 mutant motor phenotype in mice lacking dopamine D2 and D3 receptors.Neuroscience 91, 911–924.PubMedCrossRefGoogle Scholar
  33. Kakimura, J, Y Kitamura, K Takata, Y Kohno, Y Nomura and T Taniguchi (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.Eur. J. Pharmacol. 417, 59–67.PubMedCrossRefGoogle Scholar
  34. Kirkland RA, JA Windelborn, JM Kasprzak and JL Franklin (2002) A Bax-induced pro-oxidant state is critical for cytochrome c release during programmed neuronal death.J. Neurosci. 22, 6480–6490.PubMedGoogle Scholar
  35. Kitamura Y, Y Kohno, M Nakazawa and Y Nomura (1997) Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.Jpn. J. Pharmacol. 74, 51–57.PubMedCrossRefGoogle Scholar
  36. Kitamura Y, T Kosaka, JI Kakimura, Y Matsuoka, Y Kohno, Y Nomura and T Taniguchi (1998) Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.Mol. Pharmacol. 54, 1046–1054.PubMedGoogle Scholar
  37. Koeltzow TE, M Xu, DC Cooper, XT Hu, S Tonegawa, ME Wolf and FJ White (1998) Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.J. Neurosci. 18, 2231–2238.PubMedGoogle Scholar
  38. Koshimura K, J Tanaka, Y Murakami and Y Kata (2000) Effects of dopamine and L-DOPA on survival of PC12 cells.J. Neurosci. Res. 62, 112–119.PubMedCrossRefGoogle Scholar
  39. L'hirondel M, A Cheramy, G Godeheu, F Artaud, A Saiardi, E Borrelli and J Glowinski (1998) Lack of autoreceptor-mediated inhibitory control of dopamine release in striatal synaptosomes of D2 receptor-deficient mice.Brain Res. 792, 253–262.PubMedCrossRefGoogle Scholar
  40. Lai CT and PH Yu (1997) Dopamine- and L-beta-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)- induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells. Effects of oxidative stress and antioxidative factorsBiochem. Pharmacol. 53, 363–372.PubMedCrossRefGoogle Scholar
  41. Langston JW, P Ballard, JW Tetrud and I Irwin (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.Science 219, 979–980.PubMedCrossRefGoogle Scholar
  42. Langston JW, LS Forno, J Tetrud, AG Reeves, JA Kaplan and D Karluk (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure.Ann. Neurol. 46, 598–605.PubMedCrossRefGoogle Scholar
  43. Le WD, J Jankovic, W Xie and SH Appel (2000) Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection.J. Neural. Transm. 107, 1165–1173.PubMedCrossRefGoogle Scholar
  44. Le Moine C and B Bloch (1991) Rat striatal and mesencephalic neurons contain the long isoform of the D2 dopamine receptor mRNA.Brain Res. Mol. Brain Res. 10, 283–289.PubMedGoogle Scholar
  45. Ling ZD, HC Robie, CW Tong and PM Carvey (1999) Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.J. Pharmacol. Exp. Ther. 289, 202–210.PubMedGoogle Scholar
  46. Ling ZD, CW Tong and PM Carvey (1998) Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures.Brain Res. 791, 137–145.PubMedCrossRefGoogle Scholar
  47. Marek K, J Seibyl, I Shoulson, R Holloway, K Kieburtz, M McDermott, C Kamp, A Shinaman, S Fahn, A Lang, W Weiner and M Welsh (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.JAMA 287, 1653–1661.CrossRefGoogle Scholar
  48. Martel F, C Calhau and I Azevedo (2000) Characterization of the transport of the organic cation [3H]MPP+ in human intestinal epithelial (Caco-2) cells.Naunyn Schmiedebergs Arch. Pharmacol. 361, 505–513.PubMedCrossRefGoogle Scholar
  49. Masserano JM, L Gong, H Kulaga, I Baker and RJ Wyatt (1996) Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.Mol. Pharmacol. 50, 1309–1315.PubMedGoogle Scholar
  50. Matecka D, RB Rothman, L Radesca, BR de Costa, CM Dersch, JS Partilla, A Pert, JR Glowa, FH Wojnicki and KC Rice (1996) Development of novel, potent, and selective dopamine reuptake inhibitors through alteration of the piperazine ring of 1-[2-(diphenylmethoxy)ethyl]-and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazines (GBR 12935 and GBR 12909).J. Med. Chem. 39, 4704–4716.PubMedCrossRefGoogle Scholar
  51. Matsuoka I, N Mizuno and K Kurihara (1989) Cholinergic differentiation of clonal rat pheochromocytoma cells (PC12) induced by retinoic acid: increase of choline acetyltransferase activity and decrease of tyrosine hydroxylase activity.Brain Res. 502, 53–60.PubMedCrossRefGoogle Scholar
  52. McNaught KS, U Thull, PA Carrupt, C Altomare, S Cellamare, A Carotti, B Testa, P Jenner and CD Marsden (1996) Nigral cell loss produced by infusion of isoquinoline derivatives structurally related to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Neurodegeneration 5, 265–274.PubMedCrossRefGoogle Scholar
  53. Muralikrishnan D and KP Mohanakumar (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.FASEB J. 12, 905–912.PubMedGoogle Scholar
  54. Murer MG, G Dziewezapolski, LB Menalled, MC Garcia, Y Agid, O Gershanik and R Raisman-Vozari (1998) Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.Ann. Neurol. 43, 561–575.PubMedCrossRefGoogle Scholar
  55. Oyarce AM and PJ Fleming (1991) Multiple forms of human dopamine beta-hydroxylase in SH-SY5Y neuroblastoma cells.Arch. Biochem. Biophys. 290, 503–510.PubMedCrossRefGoogle Scholar
  56. Park, CW, HS Lee and YS Kim (1998) Mechanism of MPP(+)-induced cytotoxicity in human neuroblastoma SH-SY5Y.J. Toxicol. Sci. 23 Suppl 2, 184–188.PubMedGoogle Scholar
  57. Pennypacker KR, DM Kuhn and ML Billingsley (1989) Changes in expression of tyrosine hydroxylase immunoreactivity in human SMS-KCNR neuroblastoma following retinoic acid or phorbol ester-induced differentiation.Brain Res. Mol. Brain Res. 5, 251–258.PubMedCrossRefGoogle Scholar
  58. Przedborski S, V Jackson-Lewis, R Djaldetti, G Liberatore, M Vila, S Vukosavic and G, Almer (2000) The parkinsonian toxin MPTP:action and mechanism.Restorative Neurol. Neurosci. 16, 135–142.Google Scholar
  59. Ramirez AD, SK Wong and FS Menniti (2003) Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.Eur. J. Pharmacol. 475, 29–35.PubMedCrossRefGoogle Scholar
  60. Richards ML and W Sadee (1986) Human neuroblastoma cell lines as models of catechol uptake.Brain Res. 384, 132–137.PubMedCrossRefGoogle Scholar
  61. Ross RA, BA Spengler and JL Biedler (1983) Coordinate morphological and biochemical interconversion of human neuroblastoma cells.J. Natl. Cancer Inst. 71, 741–747.PubMedGoogle Scholar
  62. Sheehan JP, PE Palmer, GA Helm and JB Tuttle (1997) MPP induced apoptotic cell death in SH-SY5Y neuroblastoma cells: an electron microscope study.J. Neurosci. Res. 48, 226–237.PubMedCrossRefGoogle Scholar
  63. Simantov R, E Blinder, T Ratovitski, M, Tauber, M Gabbay and S Porat (1996) Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter.Neuroscience 74, 39–50.PubMedCrossRefGoogle Scholar
  64. Song X, S Perkins, BS Jortner and M Ehrich, (1997) Cytotoxic effects of MPTP on SH-SY5Y human neuroblastoma cells.Neurotoxicology 18, 341–353.PubMedGoogle Scholar
  65. Spina MB, SP Squinto, J Miller, RM Lindsay and C Hyman (1992) Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine andN-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system [see comments].J. Neurochem. 59, 99–106.PubMedCrossRefGoogle Scholar
  66. Stokes AH, DY Lewis, LH Lash WG Jerome, III, KW Grant, M Aschner and KE Vrana (2000) Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis.Brain Res. 858, 1–8.PubMedCrossRefGoogle Scholar
  67. Storch A, K Burkhardt, AC Ludolph and J Schwarz (2000a) Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism.J. Neurochem. 75, 2259–2269.PubMedCrossRefGoogle Scholar
  68. Storch A, A Kaftan, K Burkhardt and J Schwarz (2000b) 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism.J. Neural Transm. 107, 281–293.PubMedCrossRefGoogle Scholar
  69. Veech GA, J Dennis, PM Keeney, CP Fall, RH Swerdlow, WD Parker Jr and JP Bennett Jr (2000) Disrupted mitochondrial electron transport function increases expression of anti-apoptotic bcl-2 and bcl-X(L) proteins in SH-SY5Y neuroblastoma and in Parkinson disease cybrid cells through oxidative stress.J. Neurosci. Res. 61, 693–700.PubMedCrossRefGoogle Scholar
  70. Willets JM, DG Lambert, J Lunec and HR Griffiths (1995) Studies on the neurotoxicity of 6,7-dihydroxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (salsolinol) in SH-SY5Y cells.Eur. J. Pharmacol. 293, 319–326.PubMedCrossRefGoogle Scholar
  71. Zapata A and TS Shippenberg (2002) D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens.J. Neurochem. 81, 1035–1042.PubMedCrossRefGoogle Scholar
  72. Zapata A, JM Witkin and TS Shippenberg (2001) Selective D3 receptor agonsit effects of (+)=PD 128907 on dialysate dopamine at low doses.Neuropharmacology 41, 351–359.PubMedCrossRefGoogle Scholar
  73. Zou L, J Xu, J Jankovic, Y He, SH Appel and W Le (2000) Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice.Neurosci. Lett. 281, 167–170.PubMedCrossRefGoogle Scholar

Copyright information

© FP Graham Publishing Co 2004

Authors and Affiliations

  • Steven P. Presgraves
    • 1
  • Tariq Ahmed
    • 2
  • Sabine Borwege
    • 2
  • Jeffrey N. Joyce
    • 2
  1. 1.Molecular and Cellular Biology Graduate GroupArizona State UniversityTempe
  2. 2.Thomas H Christopher Center for Parkinson's Disease Research CenterSun Health Research InstituteSun City

Personalised recommendations